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Abstract
Objective
Successfully stopping or reducing treatment for patients with rheumatoid arthritis (RA) in low
disease activity (LDA) may improve cost-effectiveness of care. We evaluated the multi-bio-
marker disease activity (MBDA) score as a predictor of disease relapse after discontinuation
of TNF inhibitor (TNFi) treatment.
Methods
439 RA patients who were randomized to stop TNFi treatment in the POET study were ana-
lyzed post-hoc. Three indicators of disease relapse were assessed over 12 months: 1)
restarting TNFi treatment, 2) escalation of any DMARD therapy and 3) physician-reported
flare. MBDA score was assessed at baseline. Associations between MBDA score and
disease relapse were examined using univariate analysis and multivariate logistic
regression.
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Results
At baseline, 50.1%, 35.3% and 14.6% of patients had low (<30), moderate (30−44) or high
(>44) MBDA scores. Within 12 months, 49.9% of patients had restarted TNFi medication,
59.0% had escalation of any DMARD and 57.2% had1 physician-reported flare. MBDA
score was associated with each indicator of relapse. At least one indicator of relapse was
observed in 59.5%, 68.4% and 81.3% of patients with low, moderate or high MBDA scores,
respectively (P = 0.004). Adjusted for baseline DAS28-ESR, disease duration, BMI and ero-
sions, high MBDA scores were associated with increased risk for restarting TNFi treatment
(OR = 1.85, 95% CI 1.00–3.40), DMARD escalation (OR = 1.99, 95% CI 1.01–3.94) and
physician-reported flare (OR = 2.00, 95% 1.06–3.77).
Conclusion
For RA patients with stable LDA who stopped TNFi, a high baseline MBDA score was inde-
pendently predictive of disease relapse within 12 months. The MBDA score may be useful
for identifying patients at risk of relapse after TNFi discontinuation.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease that can cause joint damage and
physical disability [1]. Early detection of RA and the availability of biologic agents have
markedly improved outcomes in these patients [2]. Many studies have shown that the use of
combinations of conventional synthetic DMARDs (csDMARDs) and biological DMARDs
(bDMARDS) such as tumor necrosis factor inhibitors (TNFi) is effective for reaching and
maintaining a state of low disease activity (LDA) or remission [3–5]. Once LDA or remission
has been reached, patients often continue their combination therapy indefinitely. This practice
may lead to overtreatment, as recent studies suggest that in some RA patients the more expen-
sive TNFi can be tapered or stopped [6,7]. However, before implementing this therapeutic
strategy in routine care, a validated predictor of disease relapse would be desirable [8].
Several studies have explored predictors of successful TNFi discontinuation. Results varied
considerably, possibly due to differences in population, design and definitions of success, but
most studies identified deep remission or lower disease activity at the time of discontinuation
as a predictor [9–11]. Rheumatoid factor (RF) positivity, shorter disease duration, non-smok-
ing and normal body mass index (BMI) may also be associated with better outcomes [10,12].
Although these studies all found that some patients could discontinue TNFi treatment without
flaring, it remains a challenge to accurately predict which patients may successfully discon-
tinue treatment and which are at higher risk of disease relapse [13].
Studies of strategies for reducing DMARD treatment have mainly evaluated the predictive
value of conventional clinical measures of disease activity and traditional biomarkers such as
rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (ACPA) [10,12,14].
However, new biomarkers with interesting potential have become available. The multi-bio-
marker disease activity (MBDA) blood test measures 12 serum proteins to produce a score that
has been clinically validated as a measure of disease activity in patients with RA [15–17].
MBDA scores have been shown to reflect current clinical disease activity and changes in dis-
ease activity over time, including treatment responses in RA patients treated with TNFi [18].
The MBDA score assesses the activity of underlying biologic pathways rather than external
MBDA score as predictor of flare after stopping TNFi
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signs and symptoms and may therefore provide information that is complementary to clinical
assessment [16]. The MBDA score was a more accurate predictor of radiographic progression
than the 28-joint Disease Activity Score with C-reactive protein (DAS28-CRP) or CRP, and it
is often elevated in patients with low clinical disease activity or low CRP [18–22].
Recently, the MBDA score and ACPA were shown to be predictors of relapse for RA-
patients in stable remission when treatments with conventional DMARDs and/or biological
DMARDs were tapered, and for some patients, subsequently stopped. Prediction was strongest
when MBDA score and ACPA were combined [23]. This finding, in a study of drug tapering,
suggests that the MBDA score may be capable of predicting the outcome of complete TNFi dis-
continuation. The aim of the present study was to examine the prognostic value of the MBDA
score for disease relapse after discontinuation of TNFi in RA patients with stable LDA.
Methods
Patient cohort
Data used for these analyses were from the Dutch POET trial (the Netherlands Trial Register,
number NTR3112) [24]. The study was approved by the Ethical Review Boards of all partici-
pating hospitals. Ethical approval for the study was granted by the Committee on Research
involving Human Subjects, region Arnhem-Nijmegen (Commissie Mensgebonden Onderzoek
regio Arnhem-Nijmegen) and local feasibility by all regional Ethical Committees. Patients
were included from March 2012 to March 2014 and written informed consent was obtained
from all patients. In this pragmatic, multicenter, open-label, randomized clinical trial, RA
patients with stable LDA were randomized 2:1 to either stop or continue TNFi treatment.
Patients were included from March 2012 to March 2014 and written informed consent was
obtained from all patients. All participating patients were18 years old, had RA according to
ACR 1987 criteria, and had received TNFi treatment for at least one year prior to inclusion.
Patients had stable LDA for at least six months, defined as either two DAS28 with erythrocyte
sedimentation rate (DAS28-ESR) measurements <3.2 or a rheumatologist clinical impression
of remission or stable low disease activity and at least one CRP measurement <10 mg/L in the
six months prior to inclusion. Nearly all patients were receiving concomitant csDMARDs.
In the 6 months prior to inclusion, no dosage changes were allowed for csDMARDs or
corticosteroids.
In total, 531 patients were randomized to stop TNFi treatment in POET and followed for
12 months [24]. Concomitant treatment with csDMARDs was continued. If RA flared
(DAS28-ESR3.2 with a change in DAS28-ESR >0.6) [25], TNFi could be restarted at the dis-
cretion of the treating rheumatologist. Because the current study focused on the value of the
MBDA score as a predictor of disease relapse after discontinuation of TNFi treatment, only
data from patients randomized to the stop group were used. For the current analyses, baseline
serum samples were available to measure MBDA scores for 439 of the 531 patients in the
group that stopped TNFi treatment.
Measurements
Patients were evaluated by their treating rheumatologist and rheumatology nurse at baseline
and at least once every 3 months thereafter, for a period of one year. Baseline measures
included: age, sex, weight, height, disease duration, medication use, rheumatoid factor (RF)
and ACPA status, concomitant use of csDMARDs and, for this post hoc analysis, the MBDA
score. Clinical measurements were performed at every scheduled or unscheduled visit and
included the ESR (mm/h), CRP (mg/l), 28-joint tender joint count (TJC28), 28-joint swollen
joint count (SJC28), and a patient-reported assessment of general health on a 100 mm visual
MBDA score as predictor of flare after stopping TNFi
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analog scale (VAS-GH). These component measures were combined to calculate DAS28-ESR
[26]. Physician-reported flares and all changes in medication were recorded throughout the
study.
Serum biomarker measurement and MBDA score calculation
Serum samples were stored at −40˚C from time of preparation until transfer to Crescendo Bio-
science (South San Francisco, CA, USA), where they were stored at −70˚C or lower until bio-
marker concentration testing was performed in the Crescendo clinical laboratory, which is
certified under the CMS Clinical Laboratory Improvement Amendments and accredited by
the College of American Pathologists for determination of Vectra1 DA scores. Biomarker
concentrations were measured by electrochemiluminescence-based multiplexed immunoas-
says (Meso Scale Discovery, Rockville, MD, USA). The MBDA algorithm combines the con-
centrations of 12 biomarkers (vascular cell adhesion molecule-1 [VCAM-1], epidermal growth
factor [EGF], vascular endothelial growth factor-A [VEGF-A], interleukin [IL]-6, tumor
necrosis factor-receptor type 1 [TNF-RI], matrix metalloproteinase [MMP]-1, MMP-3, carti-
lage glycoprotein 39 [YKL-40], leptin, resistin, serum amyloid A [SAA], and CRP)[15] to gen-
erate the MBDA score on a scale of 1 to 100, with previously validated categories for low
(<30), moderate (30 to 44) and high (>44) disease activity [16].
Statistical analysis
Baseline demographic and disease-related characteristics were compared between the 439
patients with a baseline MBDA assessment and the 92 patients without an MBDA assessment
using independent samples t-tests and Mann-Whitney U tests for normally and non-normally
distributed continuous variables, and Pearson χ2 tests for categorical variables. Disease relapse
was defined three ways, using the criteria of: 1) restarting TNFi treatment, 2) any DMARD
medication escalation and 3) physician-reported flare. DMARD medication escalation was
defined as restarting TNFi treatment or starting or increasing the dosing of any bDMARD or
csDMARD (including corticosteroids) [24]. Baseline characteristics of patients who did and did
not meet the different criteria for relapse within the 12-month follow-up period were first com-
pared using univariate logistic regression analyses. Patients who dropped out before 12 months
of follow-up without meeting a criterion for relapse were counted in this analysis with those
who continued to have a response. For each criterion for relapse, the proportions of patients in
the low (<30), moderate (30–44) and high (>44) MBDA score groups who relapsed were com-
pared by univariate Pearson χ2 tests with Bonferroni adjustment for the number of comparisons
(P< (0.05 / 3 =) 0.017). Additional sensitivity analyses were performed limited to those patients
that were included based on two available DAS28 scores<3.2 in the six months prior to inclu-
sion, those who met the inclusion criteria for stable LDA but had moderate DAS28-ESR at base-
line, and those who were in remission at baseline (DAS28 scores<2.6). One-year relapse-free
survival was examined for the low, moderate, and high MBDA score groups using Kaplan-
Meier survival curves; patients who dropped out early without disease relapse were censored at
the time of withdrawal. Between-group differences in survival were tested by pairwise log-rank
tests, again with Bonferroni adjustment for the number of comparisons (P< 0.017). Based on
the results of the univariate χ2 tests and Kaplan-Meier survival analyses, baseline MBDA scores
were dichotomized as high (>44) vs. moderate-to-low (44). Cox proportional hazard regres-
sions were used to estimate the hazard ratio (HR), which may be interpreted as a relative risk, of
high vs. moderate-to-low MBDA score for the time to relapse. Next, univariate and multivari-
able logistic regression analyses were performed to evaluate the association between disease
relapse within 12 months and high baseline MBDA score in terms of unadjusted odds ratios
MBDA score as predictor of flare after stopping TNFi
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(ORs), ORs adjusted for baseline DAS28-ESR score, and ORs further adjusted for all other vari-
ables that were significantly (P< 0.05) associated with a relapse criterion in the univariate logis-
tic regression analyses. Final sensitivity analyses were performed in which all patients with a
missing visit (missing DAS28 score at 3, 6, 9, or 12 months) were counted as a flare on all flare
criteria. All analyses were performed using SPSS version 22.
Results
Demographic and clinical data at baseline
From the 531 patients who were randomized to stop TNFi treatment in POET, baseline serum
samples were available for MBDA testing for 439 patients. Among these patients, 356 (81.1%)
were included based on at least two available DAS28 scores<3.2, and 83 (18.9%) were included
based on the rheumatologist clinical impression of remission or stable low disease activity in
combination with at least one available CRP value<10 mg/L. Baseline demographic and clinical
data were similar between patients with or without a baseline MBDA sample (Table 1). Patients
were typically older Dutch Caucasian females, with longstanding RF-positive, erosive RA. Most
patients were receiving their first TNFi, with 51.3% of 439 patients receiving adalimumab,
40.1% receiving etanercept and 8.6% receiving infliximab, certolizumab or golimumab. Clinical
disease activity was generally low, in accordance with study inclusion criteria, and 349 (79.5%)
Table 1. Baseline characteristics of POET patients grouped according to sample availability for MBDA testing.
Characteristic (N = 531) MBDA sample (n = 439) No MBDA sample (n = 92) P
Female, n (%) 296 (67.4%) 66 (71.7%) 0.419
Age (yrs.), mean (SD) 59.8 (10.8) 61.7 (10.6) 0.137
Disease duration (yrs.), median (IQR) 10 (6–17) 9 (6–16) 0.535
BMI, mean (SD) 25.9 (4.3) 25.9 (4.0) 0.854
RF positive, n (%) 270 (67.3%) 58 (68.2%) 0.872
ACPA positive, n (%) 277 (69.1%) 55 (64.7%) 0.431
Erosive disease, n (%) 252 (62.8%) 53 (62.4%) 0.932
ESR, median (IQR) 9.0 (5–17) 9.5 (5–18) 0.638
CRP, median (IQR) 2 (1–5) 3 (1–5.8) 0.388
TJC28, median (IQR) 0 (0–1) 0 (0–0) 0.043
SJC28, median (IQR) 0 (0–0) 0 (0–1) 0.328
PGA, median (IQR) 20.7 (9.0–28.1) 20.4 (5.0–23.4) 0.455
DAS28-ESR 2.0 (0.8) 1.9 (0.7) 0.549
MBDA score, mean (SD) 30.2 (12.6) - -
Number of TNFi, n (%) 0.819
1st 379 (86.5%) 80 (87.0%)
2nd 50 (11.4%) 11 (12.0%)
3rd 9 (2.1%) 1 (1.1%)
csDMARD, n (%) 0.581
Methotrexate 382 (87.0%) 77 (83.7)
Other csDMARD 35 (8.0%) 8 (8.7%)
No DMARD 22 (5.0%) 7 (7.6%)
TNFi = tumor necrosis factor-alpha inhibitors; DAS28 = disease activity score in 28 joints; BMI = body mass index;
RF = rheumatoid factor; ACPA = anti-cyclic citrullinated peptide antibodies; ESR = erythrocyte sedimentation rate;
CRP = C-reactive protein; TJC28 = 28-joint tender joint count; SJC28 = 28-joint swollen joint count; PGA = patient
global assessment; MBDA = multi-biomarker disease activity; csDMARD = conventional synthetic disease modifying
anti-rheumatic drug; SD (standard deviation); IQR (interquartile range).
https://doi.org/10.1371/journal.pone.0192425.t001
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patients were in remission (DAS28-ESR<2.6) at baseline. Seventeen (3.9%) patients dropped
out during the first 12 months of follow-up because of their own decision to drop out (n = 13)
or presence of a comorbidity (n = 4).
Association between baseline MBDA score and disease relapse
Baseline MBDA scores were low (<30) in 220 (50.1%) patients, moderate (30−44) in 155
(35.3%) patients, and high (>44) in 64 (14.6%). Clinical disease activity at baseline, as mea-
sured with the DAS28-ESR, was low in 413 (94.1%) patients and moderate in 26 (5.9%)
patients. Within 12 months, 219 patients (49.9%) had restarted TNFi treatment, 259 (59.0%)
patients had escalated any DMARD, and 251 (57.2%) had experienced at least one physician-
reported flare. There was no significant difference in the proportion of patients experiencing a
relapse between those who were included based on available DAS28 scores and those who
were included based on the rheumatologist clinical impression and the CRP value (TNFi
restart: 51.4% vs. 43.4%, P = 0.188; medication escalation: 60.1% vs. 54.2%, P = 0.325; physi-
cian-reported flare: 57.3% vs. 56.6%, P = 0.911).
There was considerable overlap of the different relapse groups (Fig 1). For example, among
the 289 patients who met at least one criterion for relapse, only 12 (4.2%) restarted TNFi treat-
ment without also having a physician-reported flare, while 44 (15.2%) patients had a physi-
cian-reported flare but did not restart TNFi treatment; 207 out of 289 (71.6%) of the patients
who relapsed met all three criteria. One hundred fifty (34.2%) patients in the overall cohort
(N = 439) completed one year without meeting any of the three criteria for relapse.
Fig 1. Venn diagram of patients meeting criteria for disease relapse. Red = TNFi restart; green = medication
escalation; blue = physician-reported flare; yellow = overlap medication escalation / physician-reported flare;
grey = overlap medication escalation / TNFi restart. Percentages are for the 289 patients who met at least one of the
three criteria of disease relapse.
https://doi.org/10.1371/journal.pone.0192425.g001
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High MBDA scores (>44) at baseline were univariately associated with significantly (Bon-
ferroni adjusted P < 0.017) greater proportions of patients meeting the criteria for disease
relapse (Table 2). At least one criterion of relapse was met within 12 months of TNFi discon-
tinuation by 59.5%, 68.4% and 81.3% of patients with low, moderate, or high baseline MBDA
scores, respectively (P = 0.004). Differences in the cumulative 12-month proportions of
patients with relapse and the times to event were relatively small between patients with low or
moderate MBDA scores, but patients with high MBDA scores were clearly at increased risk.
Differences in disease relapse were very similar when limited to those patients that were
included based on two available DAS28 scores<3.2 in the six months prior to inclusion (S1
Table), although no longer significant for TNFi restart after Bonferroni adjustment. Similar
results were also obtained in a sensitivity analysis that excluded the 26 patients who met the
inclusion criteria for stable LDA but had moderate DAS28-ESR at baseline (S2 Table). Among
patients in remission at baseline (DAS28-ESR <2.6), differences between MBDA categories
were slightly less pronounced and not significant after Bonferroni correction (S3 Table).
Univariate Kaplan-Meier survival analyses confirmed the significantly decreased one-year
relapse-free survival in patients with high baseline MBDA scores (Fig 2). Pairwise differences
in one-year relapse-free survival were not significant between patients with low or moderate
MBDA scores, but patients with high MBDA scores had significantly (Bonferroni adjusted
P< 0.017) worse relapse-free survival than patients with either moderate or low MBDA scores
for all three criteria of relapse. The HRs of high vs. moderate-to-low baseline MBDA scores
were 1.61 (95% CI 1.15–2.25, P = 0.005) for TNFi restart, 1.66 (95% CI 1.22–2.26, P = 0.001)
for medication escalation, and 1.64 (95% CI 1.20–2.25, P = 0.002) for physician-reported flare.
Univariate and multivariate analysis of risk factors for disease relapse at 12
months
In univariate logistic regression analyses, greater disease duration was significantly associated
with all three criteria for disease relapse at 12 months (ORs 1.04–1.05, 95% CI 1.01–1.08) (S4
Table). Higher BMI was associated with increased odds of restarting TNFi (OR 1.05, 95% CI
1.01–1.10), medication escalation (OR 1.07, 95% CI 1.02–1.13) and any criterion (OR 1.06,
95% CI 1.01–1.12). Erosive disease was significantly associated with restarting TNFi (OR 1.62,
95% CI 1.08–2.44), but not with the other two criteria. Baseline DAS28-ESR was significantly
associated with medication escalation (OR 1.57, 95% CI 1.21–2.04), physician-reported flare
(OR 1.36, 95% CI 1.06–1.75) and any criterion (OR 1.65, 95% CI 1.26–2.17), but not with
restarting TNFi treatment (OR 1.25, 95% CI 0.98–1.60).
In multivariate analysis with adjustment for baseline DAS28-ESR, disease relapse after stop-
ping TNFi treatment was more than twice as likely to occur in patients with a high baseline
MBDA score, regardless of the relapse criterion used (Table 3). After adjusting for baseline
DAS28-ESR, disease duration, BMI and erosions, high baseline MBDA score remained a sig-
nificant independent predictor of disease relapse by all three criteria (Table 3). However, it did
Table 2. Disease relapse by three criteria at 12 months for patients classified by baseline MBDA score.
Criterion for relapse Total Low (<30); n = 220 Moderate (30–44); n = 155 High (>44); n = 64 P
TNFi restart 219 102 (46.4%) 74 (47.7%) 43 (67.2%) 0.011
Medication escalation 259 117 (53.2%) 92 (59.4%) 50 (78.1%) 0.002
Physician-reported flare 251 116 (52.7%) 87 (56.1%) 48 (75.0%) 0.006
Any criterion 289 131 (59.5%) 106 (68.4%) 52 (81.3%) 0.004
Any criterion = TNFi re-initation, medication escalation, or physician-reported flare. P-value by Pearson χ2 test. Total N = 439.
https://doi.org/10.1371/journal.pone.0192425.t002
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not remain significantly associated with the composite definition of relapse in the fully
adjusted model. In a final sensitivity analysis in which all patients with a missing visit were
counted as a flare, high MBDA score remained a significant predictor of clinical flare and a
marginally significant predictor of medication escalation and TNFi-restart (S5 Table).
Discussion
Our analyses of the POET study show that, for RA patients in remission or stable LDA, a high
MBDA score at the time of TNFi discontinuation was significantly associated with disease
relapse during the next 12 months. Over 80% of patients with a high baseline MBDA score
relapsed according to at least one of the three criteria we used. This rate of relapse was substan-
tially higher for patients with low or moderate MBDA scores, suggesting that patients with low
clinical disease activity and high MBDA scores may have inflammation that is partly or entirely
Fig 2. Kaplan-Meier survival curves. Low MBDA scores (<30, green; n = 220), moderate MBDA scores (30–44, blue;
n = 155), high MBDA scores (>40, red; n = 64) for three definitions of disease relapse. TNFi restart (top), medication
escalation (middle) and physician-reported flare (bottom).
https://doi.org/10.1371/journal.pone.0192425.g002
Table 3. Univariate and multivariate analyses of high (>44) versus moderate or low baseline MBDA score as a predictor of disease relapse at 12 months.
Unadjusted Adjusted Fully adjusted
Criterion for relapse OR (95% CI) P OR (95% CI) P OR (95% CI) P
TNFi restart
MBDA >44 2.32 (1.32–4.05) 0.003 2.17 (1.23–3.83) 0.008 1.85 (1.00–3.40) 0.049
DAS28-ESR 1.17 (0.91–1.51) 0.219 1.10 (0.84–1.45) 0.474
Disease duration 1.05 (1.02–1.08) <0.001
BMI 1.06 (1.01–1.11) 0.031
Erosive 1.30 (1.00–3.40) 0.248
Medication escalation
MBDA >44 2.84 (1.52–5.31) 0.001 2.44 (1.29–4.62) 0.006 1.99 (1.01–3.94) 0.047
DAS28-ESR 1.47 (1.13–1.92) 0.004 1.48 (1.11–1.97) 0.008
Disease duration 1.04 (1.01–1.06) 0.011
BMI 1.07 (1.01–1.13) 0.014
Erosive 1.24 (0.79–1.97) 0.353
Physician-reported flare
MBDA >44 2.54 (1.39–4.64) 0.002 2.31 (1.25–4.25) 0.007 2.00 (1.06–3.77) 0.033
DAS28-ESR 1.27 (0.98–1.65) 0.069 1.20 (0.92–1.58) 0.184
Disease duration 1.04 (1.01–1.06) 0.007
BMI 1.03 (0.98–1.08) 0.228
Erosive 1.08 (0.69–1.68) 0.784
Any criterion
MBDA >44 2.52 (1.30–4.89) 0.006 2.12 (1.08–4.16) 0.029 1.68 (0.83–3.40) 0.147
DAS28-ESR 1.56 (1.18–2.07) 0.002 1.54 (1.14–2.07) 0.005
Disease duration 1.04 (1.01–1.07) 0.010
BMI 1.06 (1.00–1.12) 0.037
Erosive 1.25 (0.78–3.40) 0.347
DAS28-ESR, disease duration and BMI were analyzed as continuous variables; MBDA score (>44) and erosive (yes/no) were analyzed as categorical variables.
Adjusted = adjusted for DAS28. Fully adjusted = adjusted for DAS28, disease duration, BMI and erosions. Any criterion includes patients with TNFi re-initation,
medication escalation or physician-reported flare. Total N = 439. See Table 2 for n-values by relapse criterion.
https://doi.org/10.1371/journal.pone.0192425.t003
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subclinical. Several other studies have found the MBDA score to be frequently elevated when
conventional clinical measures indicate remission or LDA [19,20,22,23]. Moreover, such
patients were at increased risk for progressive joint damage [19,20,22]. Consequently, discon-
tinuation of TNFi treatment in POET may have allowed a resurgence of residual inflammation
and subsequent clinical relapse [23]. Our finding that the MBDA score was a predictor of
relapse independently of DAS28-ESR suggests that it may be a clinically useful tool for identi-
fying patients who are at increased risk of unsuccessful TNFi discontinuation.
Although high MBDA was an independent predictor of three predefined criteria for relapse
(TNFi restart, medication escalation, and physician-reported flare), it should be noted that it
did not remain significantly associated with meeting any criterion of flare when adjusting for
all other potential predictors, including DAS28 score. Previous studies have explored predic-
tors of disease relapse after TNFi discontinuation and, although results varied considerably,
greater clinical disease activity at the time of discontinuation has been identified as a predictor
[9–11]. Likewise, our study found that higher baseline DAS28-ESR scores were associated with
two criteria for disease relapse, but not with the criterion of restarting TNFi treatment.
In other studies, RF positivity, shorter disease duration, non-smoking and normal body mass
index (BMI) have been associated with successful TNFi discontinuation [10,12]. In the current
study, higher BMI scores were univariately associated with increased odds of meeting two criteria
of disease relapse but not physician-reported flare, and longer disease duration was a strong pre-
dictor for all three definitions of disease relapse. Erosive disease was univariately associated with
TNFi restart. Neither positivity for RF nor ACPA was associated with disease relapse.
We previously demonstrated that RA patients in remission or stable low disease activity, as
defined by the DAS28-ESR, had a relapse risk of approximately 50% within 12 months of dis-
continuing TNFi treatment in the POET study [24]. With such a high likelihood of relapsing,
it may be helpful to have an effective tool to predict the outcome of treatment withdrawal. The
MBDA score has been shown to correlate significantly with the DAS28-ESR, DAS28-CRP,
simplified disease activity index (SDAI) and clinical disease activity index (CDAI), both overall
and in seronegative and seropositive RA patients [16,27,28]. The MBDA score was an indepen-
dent predictor of disease relapse in a study of RA patients in clinical remission who tapered,
and in one arm of the study stopped, all RA therapy, including csDMARDs and bDMARDs
[18]. The present study is the first to demonstrate the utility of the MBDA score as a predictor
for risk of disease relapse in RA patients who discontinued TNFi treatment at baseline.
Patients with high MBDA had an odds ratio of approximately 2 for experiencing a relapse
as defined by the three criteria. However, the proportion of patients with low or moderate
MBDA scores who still relapsed within 12 months was also quite high, which may limit the
utility of the MBDA to guide TNFi discontinuation in clinical practice. Additionally, since
odds ratios tend to overestimate the probability of frequent events (the overall prevalence of
relapse ranged from approximately 50%–60% on the different criteria), the hazard ratios or rel-
ative risks of around 1.6 found in the one-year survival analyses may be a more appropriate
and precise estimate of risk for relapse associated with high MBDA.
Our study has several strengths. The data we analyzed were collected in POET, the largest
randomized controlled trial on stopping TNFi in RA patients in remission or stable low disease
activity to date. The MBDA score was measured in an unbiased selection of 439 patients in the
stop group, comprising 83% of those who stopped TNFi treatment in POET. Most patients in
our study had long disease duration (i.e., established RA) and an average age of 60 years,
which is representative of the TNFi-using RA population in The Netherlands. Our finding that
MBDA score was a predictor of relapse risk is strengthened by our having used 3 different defi-
nitions of disease relapse: 1) restarting TNFi treatment, 2) escalation of any DMARD therapy
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and 3) physician-reported flare, which identified more relapses than with any one criterion
alone. MBDA scores at baseline were predictive of each definition of disease relapse.
A limitation of the study is that MBDA score was measured only at baseline. Longitudinal
measurements may have provided insight into the effect of TNFi discontinuation on MBDA
scores over time, and the potential for early change in MBDA score to predict relapse.
Although only the MBDA score has been validated for measuring disease activity, it remains to
be explored if any of the 12 biomarkers in the MBDA score might individually have ability to
predict disease relapse.
In conclusion, for RA patients in remission or stable LDA, a high baseline MBDA score was
frequently observed and was found to be an independent predictor of disease relapse within 12
months of TNFi discontinuation. These results suggest that the MBDA score may be a clini-
cally useful tool for identifying subgroups of patients who have an increased risk of relapse
when stopping TNFi treatment. These data should be confirmed in other studies.
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